Turbocharge CAR-T Manufacturing: Industrializing Cell Therapy with Perfusion

As the field transitions toward scalable, cost-efficient allogeneic CAR-T therapies, manufacturing intensification is no longer optional, it is essential.

This webinar demonstrates how perfusion using XCell® ATF technology enables rapid, high-density CAR-T expansion in stirred-tank bioreactors while preserving critical quality attributes. Data from intensified 2 L perfusion processes show consistent production of >110 anti-CD19 CAR-T doses within a 12-day manufacturing cycle, using serum-free media and optimized perfusion strategies.

We will present predictive scale-down modeling from Ambr® 250 STR to 2 L scale, stable process control with matched volumetric power input (P/V), and real-time viable cell monitoring using multi-frequency capacitance. We will also cover seamless downstream integration with automated harvest systems such as Ksep®, achieving >90% recovery. Attendees will gain practical insight into how perfusion using XCell® ATF System reduces timelines, increases yields, improves process control, and establishes a scalable, economically viable CAR-T manufacturing platform.

Key Learning Objectives:
~ How matched volumetric power input (P/V) enables predictive scale-down modeling and de-risked tech transfer from Ambr® 250 to 2 L scale
~ Why XCell ATF perfusion delivers ~34% greater fold expansion than G-Rex® systems and how multi-frequency capacitance enables real-time viable cell density prediction
~ How to integrate automated harvest systems (e.g., Ksep®) for >90% recovery in an industrialized allogeneic CAR-T workflow